“Apellis is developing APL-2, an investigational C3 inhibitor for complement-mediated diseases. In our view, APLS shares offer a compelling risk-reward profile due to the large market potential and compelling efficacy profile in PNH and geographic atrophy (GA). Valuation Summary We arrive at our 12-month price target of $53/share by assessing the after-tax, risk- adjusted NPV of potential future cash flows from APL-2.”,” Cantor Fitzgerald’s analyst wrote.
APLS has been the subject of a number of other research reports. Zacks Investment Research lowered shares of Apellis Pharmaceuticals from a hold rating to a sell rating in a research note on Monday, June 25th. Cowen started coverage on shares of Apellis Pharmaceuticals in a research note on Tuesday, July 10th. They issued an outperform rating and a $40.00 price target for the company. Finally, B. Riley upgraded shares of Apellis Pharmaceuticals from a neutral rating to a buy rating and set a $27.00 price target for the company in a research note on Monday, July 30th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the company’s stock. The stock has an average rating of Buy and an average price target of $33.83.
Shares of NASDAQ:APLS opened at $17.77 on Tuesday. The company has a debt-to-equity ratio of 0.12, a current ratio of 26.02 and a quick ratio of 26.02. Apellis Pharmaceuticals has a 12-month low of $12.45 and a 12-month high of $32.00.
Apellis Pharmaceuticals (NASDAQ:APLS) last issued its quarterly earnings results on Tuesday, July 31st. The company reported ($0.61) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.14). sell-side analysts predict that Apellis Pharmaceuticals will post -2.2 EPS for the current year.
Hedge funds have recently added to or reduced their stakes in the business. Legal & General Group Plc increased its stake in Apellis Pharmaceuticals by 186.1% during the second quarter. Legal & General Group Plc now owns 5,385 shares of the company’s stock valued at $118,000 after purchasing an additional 3,503 shares during the last quarter. MetLife Investment Advisors LLC bought a new stake in Apellis Pharmaceuticals during the first quarter valued at $126,000. Wells Fargo & Company MN increased its stake in Apellis Pharmaceuticals by 285.3% during the first quarter. Wells Fargo & Company MN now owns 6,149 shares of the company’s stock valued at $136,000 after purchasing an additional 4,553 shares during the last quarter. PNC Financial Services Group Inc. bought a new stake in Apellis Pharmaceuticals during the second quarter valued at $162,000. Finally, Rhumbline Advisers bought a new stake in Apellis Pharmaceuticals during the first quarter valued at $206,000. Hedge funds and other institutional investors own 51.68% of the company’s stock.
About Apellis Pharmaceuticals
Apellis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutic compounds for autoimmune and inflammatory diseases. Its lead product candidate is APL-2 to treat geographic atrophy, wet age-related macular degeneration, paroxysmal nocturnal hemoglobinuria, autoimmune hemolytic anemia, and nephrology.
Recommended Story: Asset Allocation Models, Which is Right For You?
Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.